Health News

CureVac CEO eyes COVID-19 vaccine approval in third quarter 2021

FILE PHOTO: An employee of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen, Germany, March 12, 2020. REUTERS/Andreas Gebert

BERLIN (Reuters) - German biotech company CureVac 5CV.DE hopes to receive approval for its experimental COVID-19 vaccine in the third quarter of 2021, Chief Executive Franz-Werner Haas said on Thursday.

Haas told a news conference of foreign journalists that the company aimed to initiate rolling review of its vaccine in the first quarter of 2021.

The exact timing for final approval will depend on how many other shots are given the green light over the next few months, he added.

Reporting by Caroline Copley and Ludwig Burger; Editing by Maria Sheahan